Navigation Links
ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood
Date:11/8/2007

t patients suffering from other dementias such as frontal lobe dementias, Lewy body dementias or vascular dementias. This will be validated in mid-2008, after we have compared our signature to the clinical diagnostic criterias for these dementias" declared Laurent Bracco, Executive Vice President for Research at ExonHit Therapeutics.

"We are making good progress towards having our first diagnostic certified. We will be able to provide it as a service in Europe and in the USA, to companies interested in recruiting patients with a specific blood signature, as well as meeting the current recruitment criteria" stated Bruno Tocque, President of the Management Board of ExonHit. He added "There are approximately 140 clinical trials ongoing in Alzheimer's disease. This is an ideal market for ExonHit".

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases an
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... how the receptors responsible for contractions in the bladder, ... published today in The FASEB Journal , has ... cycle of all cells in the body. The team ... and its control are weakened in ageing bladders, demonstrating ... ageing. , While currently much is known ...
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... , , NEW YORK, Sept. ... with Dave Champagne, Vice President and General Manager of Informatics ... Chief Engineer at HUNT Research Center and Biobank, about data ... and challenges at life sciences companies. , ...
... , , BALTIMORE, Sept. 9 ... a company engaged in the development of advanced preclinical platforms and ... present at Rodman & Renshaw,s Eleventh Annual Healthcare Conference taking place ... The company,s Chairman of the Board, Dr. David Sidransky, will present ...
... 9 Oramed Pharmaceticals,Inc. (OTCBB: ORMP.OB), a developer of ... approval from the Institutional Review Board (IRB),to commence human ... was,granted after successful pre-clinical results were reported. The trials ... Center in,Jerusalem. , Currently, all ...
Cached Biology Technology:Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 3Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 2Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 3
(Date:8/22/2014)... Access to Research Careers) Program has announced the travel ... Practical Exercises Workshop which will be held on the ... 2014. These awards are meant to help support ... groups in the the FASEB Grant Writing Seminar & ... awards totaling $20,350. , The FASEB MARC Program is ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... reconstructions of atmospheric CO2 concentrations and sea level over ... National Oceanography Centre, Southampton have found that greenhouse gas ... million) were systematically associated with sea levels at least ... determined the ,natural equilibrium, sea level for CO2 concentrations ...
... learn that plants grow toward the light. This seems straightforward, ... to grow and move in response to their environment are ... most fundamental processes in plant biologyplant movement in response to ... American Journal of Botany . Plant movements, known ...
... have cast doubt on the widely held perception that ... Blooms, or proliferations, of jellyfish can show a substantial, ... fishermen, stinging waters for tourists, even choked cooling intake ... have created a perception that the world,s oceans are ...
Cached Biology News:New study documents the natural relationship between CO2 concentrations and sea level 2Scientists join forces to bring plant movement to light 2Scientists join forces to bring plant movement to light 3Scientists join forces to bring plant movement to light 4Jellyfish experts show increased blooms are a consequence of periodic global fluctuations 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
Biology Products: